Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001750 · ClinicalTrials.gov registry record · Phase 2
Comparing Treatments for Multiple Myeloma
A Phase 2 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00001750 is a Phase 2 study that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 32 participants.
The verdict
NCT00001750, a Phase 2 study, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
Some drugs have the ability to push stem cells (the cells responsible for producing new cell types) out of the bone marrow and into the blood stream. The steps involved in this process are still poorly understood. However, a better understanding of this process could lead to improved results in transplantation, cancer treatment, and contribute to the development of new genetic therapies for a wide variety of disorders. In this study researchers plan to compare two different treatments, both that mobilize (push) stem cells out of the bone marrow into the blood stream. In addition, researchers will attempt to determine which is the most efficient at mobilizing blood cells of patients with multiple myeloma. Information and knowledge gained from this study will help to design future transplantation and genetic therapy research studies.
Interventions
- DRUG Stemgen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 1998-09 |
| Est. Completion | 2002-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001750
The ClinicalTrials.gov registry entry for NCT00001750 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Stemgen is the first listed.
NCT00001750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001750 about?
NCT00001750 is a clinical study titled "Comparing Treatments for Multiple Myeloma". Some drugs have the ability to push stem cells (the cells responsible for producing new cell types) out of the bone marrow and into the blood stream. The steps involved in this process are still poorly understood. However, a better understanding of this process could lead to improved results in tran...
What is the current status of trial NCT00001750?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 1998-09. Estimated completion is 2002-08.
What interventions are being tested in trial NCT00001750?
The interventions under investigation include: Stemgen (DRUG).
Who is sponsoring clinical trial NCT00001750?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.